Targeted Therapeutics Market Size, Share, Growth Analysis, By Type(Monoclonal Antibodies and Small Molecule), By Application(Breast Cancer, Colorectal Cancer, Lung Cancer, Renal Cancer), By Region - Industry Forecast 2024-2031

Global targeted therapeutics market is highly competitive with the presence of local as well as global companies. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of global targeted therapeutics market.

For example, on July 21, 2021, United Kingdom-based pharmaceutical giant AstraZeneca announced that it had closed the acquisition process for US-based biopharmaceutical company, Alexion Pharmaceuticals. AstraZeneca paid Alexion USD 39 billion. The move will give AstraZeneca an opportunity to expand its expertise in immunology and in rare medicines.

Top Player's Company Profiles

• Roche Holding AG
• Novartis AG
• Amgen Inc.
• AstraZeneca Plc
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Company
• Bayer AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• AbbVie Inc.
• Biogen Inc.
• Sanofi S.A.
• Johnson & Johnson
• Takeda Pharmaceutical Co. Ltd.
• Gilead Sciences Inc.
• Vertex Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company)
• Regeneron Pharmaceuticals Inc.

Recent Developements

• In January 2024, Remix Therapeutics started a strategic collaboration with Roche, which is pointed toward utilizing RNA modulation for novel drug discovery efforts.
• In October 2023, Medilink Therapeutics uncovered a strategic collaboration and overall license agreement with BioNTech to advance the improvement of the cutting-edge enemy of cancer antibody drug forms.
• In October 2023, Monte Rosa Therapeutics disclosed a strategic collaboration with Roche to discover novel molecular glue degraders targeting malignant growth and neurological diseases.